UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

Journal of Nuclear Medicine, 2016-10, Vol.57 (Suppl 3), p.97S-104S

2016

Link zum Volltext

Verfügbarkeit prüfen

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

Theranostics, 2012-01, Vol.2 (5), p.437-447

2012

Link zum Volltext

Verfügbarkeit prüfen

Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms

Seminars in nuclear medicine, 2012-05, Vol.42 (3), p.190-207

2012

Link zum Volltext

Verfügbarkeit prüfen

Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases

Neuroendocrinology, 2018-01, Vol.106 (1), p.74-88

2018

Link zum Volltext

Verfügbarkeit prüfen

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

The Journal of nuclear medicine (1978), 2022-03, Vol.63 (3), p.415-423

2022

Link zum Volltext

Verfügbarkeit prüfen

Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues

Seminars in nuclear medicine, 2016-05, Vol.46 (3), p.215-224

2016

Link zum Volltext

Verfügbarkeit prüfen

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Diagnostics (Basel), 2022-08, Vol.12 (8), p.1926

2022

Link zum Volltext

Verfügbarkeit prüfen

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

The Journal of nuclear medicine (1978), 2022-08, Vol.63 (8), p.1199-1207

2022

Link zum Volltext

Verfügbarkeit prüfen

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Journal of Nuclear Medicine, 2019-03, Vol.60 (3), p.377-385

2019

Link zum Volltext

Verfügbarkeit prüfen

Advances in the Diagnosis of Neuroendocrine Neoplasms

Seminars in nuclear medicine, 2016-09, Vol.46 (5), p.395-404

2016

Link zum Volltext

Verfügbarkeit prüfen

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides

PloS one, 2016-09, Vol.11 (9), p.e0162303-e0162303

2016

Link zum Volltext

Verfügbarkeit prüfen

177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney

The Journal of nuclear medicine (1978), 2019-11, Vol.60 (11), p.1579

2019

Link zum Volltext

Verfügbarkeit prüfen

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

Journal of Nuclear Medicine, 2017-01, Vol.58 (1), p.75-80

2017

Link zum Volltext

Verfügbarkeit prüfen

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Journal of Nuclear Medicine, 2022-08, Vol.63 (8), p.1199-1207

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT

PET clinics, 2014-01, Vol.9 (1), p.83

2014

Link zum Volltext

Verfügbarkeit prüfen

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

British journal of radiology, 2018-11, Vol.91 (1091), p.20180308-20180308

2018

Link zum Volltext

Verfügbarkeit prüfen

225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation

Clinical nuclear medicine, 2021-12, Vol.46 (12), p.1030

2021

Link zum Volltext

Verfügbarkeit prüfen

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

European journal of nuclear medicine and molecular imaging, 2021-01, Vol.48 (1), p.113-122

2021

Link zum Volltext

Verfügbarkeit prüfen

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT

European journal of nuclear medicine and molecular imaging, 2016-05, Vol.43 (5), p.964-973

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

EJNMMI research, 2019-07, Vol.9 (1), p.1-10, Article 68

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of 18 F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2020-11, Vol.61 (11), p.1560-1569

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

Dalton transactions : an international journal of inorganic chemistry, 2017-10, Vol.46 (42), p.14638-14646

2017

Link zum Volltext

Verfügbarkeit prüfen

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors

Clinical nuclear medicine, 2023-03, Vol.48 (3), p.221

2023

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

European journal of nuclear medicine and molecular imaging, 2015-07, Vol.42 (8), p.1223-1230

2015

Link zum Volltext

Verfügbarkeit prüfen

Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy

Clinical nuclear medicine, 2020-04, Vol.45 (4), p.e198

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(100)
Buchkapitel
(4)

Sprache

Englisch
(103)
Japanisch
(7)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(49)
Science & Technology
(39)
Life Sciences & Biomedicine
(36)
Male
(32)
Radiology, Nuclear Medicine & Medical Imaging
(25)
Aged
(23)
Middle Aged
(23)
Female
(19)
Octreotide - Analogs & Derivatives
(19)
Prostate Cancer
(17)
Radiopharmaceuticals - Therapeutic Use
(15)
Neuroendocrine Tumors - Radiotherapy
(14)
Treatment Outcome
(14)
Adult
(13)
Octreotide - Therapeutic Use
(13)
Metastasis
(12)
Patients
(12)
Neuroendocrine Tumors - Diagnostic Imaging
(11)
Neuroendocrine Tumors - Pathology
(11)
Metastases
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms

Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Advances in the Diagnosis of Neuroendocrine Neoplasms

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides

177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

Prognostic Value of 18 F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors

Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy

Suchergebnisse filtern